Corporate Magazine 2012 - Boehringer Ingelheim

BOEHRINGER INGELHEIM ONCOLOGY FRANCHISE[ overview of compounds in development ]head and neck cancer [ scchn ]*AFATINIB PHASE IIIacute myeloid leukaemia [ aml ]*VOLASERTIB PHASE IIIbreast cancer [ bc ]AFATINIB PHASE IIInon-small cell lung cancer [ nsclc ]*AFATINIB PHASE IIININTEDANIB PHASE IIIovarian cancer[ oc ]NINTEDANIB PHASE IIIliver cancer [ hcc ]*NINTEDANIB PHASE IIcolorectal cancer [ crc ]*NINTEDANIB PHASE IIrenal cell cancer [ rcc ]*NINTEDANIB PHASE II* Can affect both males and females. AML source is bone marrow/spinal cord.PIONEERING TREATMENTSFOR CANCERBoehringer Ingelheim is applying scientific discoveries and researchadvances in cancer biology to develop a wide range of novel therapiesin areas of unmet medical needs in both solid tumours and haematologicalmalignancies. We are committed to the clinical developmentof pioneering treatments for cancer.Our oncology pipeline is evolving anddemonstrates the company’s continuedcommitment to advance in this diseasearea. The current focus of clinical researchincludes compounds in threeareas: signal transduction inhibition,angiogenesis inhibition and cell-cyclekinase inhibition.AfatinibAfatinib is an irreversible ErbB familyblocker which inhibits signal transductionof all kinase receptors from theErbB family, which is known to play acritical role in the growth and spreadof the most pervasive cancers and cancersassociated with high mortality,lung, breast, and head and neck cancers.Afatinib is currently in phase IIIdevelopment in non-small cell lungcancer (NSCLC), head and neck cancer,and breast cancer.Lung cancerLung cancer is the most common andmost deadly form of cancer in the world:it accounts for 1.6 million new cases inEurope annually. Because of its poorprognosis, 1.38 million deaths each yearare attributable to lung cancer.Most patients with advanced or metastaticlung cancer are treated withchemotherapy regimens. Due to unsatisfactorytreatment results in patientswith advanced non-small cell lung cancer,research and development projectsare accelerating the identification ofnew treatment strategies for this disease.LUX®-Lung 3 trialLUX®-Lung 3 is a large, randomised,open-label, phase III registration studycomparing afatinib to a combinationof two chemotherapy agents, peme-48 Boehringer Ingelheim annual report 2012